Search
Oxycodegol
go.drugbank.com/drugs/DB14146InvestigationalLoxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain [L3263]. … Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263]
DL-dimyristoylphosphatidylcholine
go.drugbank.com/drugs/DB11283ApprovedA synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes. It is used in commercial drug preparations to solubilize drugs for injection
Asunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawn[A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113] … It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b.
Foreskin fibroblast (neonatal)
go.drugbank.com/drugs/DB10770ApprovedDermagraft was introduced in the United Kingdom in October 1997, and several other European countries, as well as New Zealand and Australia. … Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997.
Patisiran
go.drugbank.com/drugs/DB14582ApprovedIt is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … The approval for Onpattro was granted to Alnylam Pharmaceuticals, Inc. in August of 2018. Onpattro has been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations.
Estramustine
go.drugbank.com/drugs/DB01196ApprovedWithdrawnA nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.
Denileukin diftitox
go.drugbank.com/drugs/DB00004ApprovedInvestigational[A264344] In 2014, it was withdrawn voluntarily from the market due to manufacturing issues; however, the biologics license application (BLA) for denileukin diftitox was resubmitted, and it was approved … [A264349, L51254] Denileukin diftitox was originally approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL),[A264339, L51264] making it the first fusion protein cytotoxin
Samarium (153Sm) lexidronam
go.drugbank.com/drugs/DB05273ApprovedSamarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical.
Tolnaftate
go.drugbank.com/drugs/DB00525ApprovedVet approvedIt may come as a cream, powder, spray, or liquid aerosol, and is used to treat jock itch, athlete's foot and ringworm. It is sold under several brand names, most notably Tinactin and Odor Eaters.
Ethchlorvynol
go.drugbank.com/drugs/DB00189ApprovedIllicitWithdrawnIt has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.